Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.

Publication Type:

Journal Article


Cancer, Volume 113, Issue 11, p.3181-5 (2008)


Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Core Binding Factors, Cytarabine, Disease-Free Survival, Female, Granulocyte Colony-Stimulating Factor, Humans, Idarubicin, Leukemia, Myeloid, Acute, Male, Middle Aged, Multivariate Analysis, Vidarabine


Acute myelogenous leukemia (AML) associated with core-binding-factor (CBF) abnormalities is the type of leukemia most responsive to cytarabine (ara-C) therapy and is of relative favorable prognosis. In vitro and ex vivo observations suggest that increases in intracellular ara-C levels influenced by administration of fludarabine and granulocyte colony-stimulating factor (GCSF) increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations.